Emerging AI-based technologies are galvanizing a new generation of data-driven machinery in the biopharmaceutical industry.

Gene editing technologies have cemented their place as a valued method in the biological toolkit used by researchers around the globe.

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.